Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 406

1.

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity.

Shi W, Ng CKY, Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Gerstein MB, Chagpar AB, Weigelt B, Pusztai L, Reis-Filho JS, Hatzis C.

Cell Rep. 2018 Nov 6;25(6):1446-1457. doi: 10.1016/j.celrep.2018.10.046.

2.

Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer.

Kratz J, Burkard M, O'Meara T, Pusztai L, Veitch Z, Bedard PL.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):56-64. doi: 10.1200/EDBK_200731.

3.

Immunological differences between primary and metastatic breast cancer.

Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L.

Ann Oncol. 2018 Sep 10. doi: 10.1093/annonc/mdy399. [Epub ahead of print]

PMID:
30203045
4.

Increased epigenetic age in normal breast tissue from luminal breast cancer patients.

Hofstatter EW, Horvath S, Dalela D, Gupta P, Chagpar AB, Wali VB, Bossuyt V, Storniolo AM, Hatzis C, Patwardhan G, Von Wahlde MK, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L.

Clin Epigenetics. 2018 Aug 29;10(1):112. doi: 10.1186/s13148-018-0534-8.

5.

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0213. doi: 10.1634/theoncologist.2018-0213. [Epub ahead of print]

PMID:
30139836
6.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

PMID:
30137196
7.

Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.

Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li FY, Zhou Y, Chagpar A, Ferrucci LM, Pusztai L, Irwin ML.

Breast Cancer Res Treat. 2018 Nov;172(1):105-112. doi: 10.1007/s10549-018-4895-7. Epub 2018 Jul 30.

PMID:
30062572
8.

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C.

JAMA Oncol. 2018 Nov 1;4(11):e181564. doi: 10.1001/jamaoncol.2018.1564. Epub 2018 Nov 8.

PMID:
29902299
9.

Variations of the Hydrogen Bonding and Hydrogen-Bonded Network in Ethanol-Water Mixtures on Cooling.

Pothoczki S, Pusztai L, Bakó I.

J Phys Chem B. 2018 Jul 5;122(26):6790-6800. doi: 10.1021/acs.jpcb.8b02493. Epub 2018 Jun 25.

PMID:
29893130
10.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.

PMID:
29793946
11.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805. No abstract available.

PMID:
29701764
12.

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

13.

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.

Pelekanou V, Barlow WE, Nahleh ZA, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L.

Mol Cancer Ther. 2018 Jun;17(6):1324-1331. doi: 10.1158/1535-7163.MCT-17-1005. Epub 2018 Mar 27.

PMID:
29588392
14.

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.

Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L.

Br J Cancer. 2018 Apr;118(8):1107-1114. doi: 10.1038/s41416-018-0030-0. Epub 2018 Mar 21.

PMID:
29559730
15.

Exercise and weight loss interventions and miRNA expression in women with breast cancer.

Adams BD, Arem H, Hubal MJ, Cartmel B, Li F, Harrigan M, Sanft T, Cheng CJ, Pusztai L, Irwin ML.

Breast Cancer Res Treat. 2018 Jul;170(1):55-67. doi: 10.1007/s10549-018-4738-6. Epub 2018 Mar 6.

PMID:
29511965
16.

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.

Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L.

Breast Cancer Res Treat. 2018 Jun;169(2):333-340. doi: 10.1007/s10549-017-4653-2. Epub 2018 Feb 2.

PMID:
29396664
17.

Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.

Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L.

JAMA Oncol. 2018 Apr 12;4(4):e175092. doi: 10.1001/jamaoncol.2017.5092. Epub 2018 Apr 12.

PMID:
29372234
18.

Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A.

J Cancer Res Clin Oncol. 2018 Mar;144(3):601-606. doi: 10.1007/s00432-017-2574-4. Epub 2018 Jan 17.

PMID:
29344722
19.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E.

Breast Cancer Res Treat. 2018 Apr;168(3):631-638. doi: 10.1007/s10549-017-4628-3. Epub 2017 Dec 27.

PMID:
29280043
20.

Functional germline variants as potential co-oncogenes.

Agarwal D, Nowak C, Zhang NR, Pusztai L, Hatzis C.

NPJ Breast Cancer. 2017 Nov 22;3:46. doi: 10.1038/s41523-017-0051-5. eCollection 2017. Review.

21.

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.

Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB.

J Oncol Pract. 2017 Dec;13(12):e1012-e1020. doi: 10.1200/JOP.2017.022731. Epub 2017 Oct 19.

PMID:
29048991
22.

Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?"

Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR.

Am J Surg. 2017 Dec;214(6):1089-1090. doi: 10.1016/j.amjsurg.2017.09.025. Epub 2017 Sep 30. No abstract available.

PMID:
28987415
23.

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT.

Ann Oncol. 2017 Oct 1;28(10):2420-2428. doi: 10.1093/annonc/mdx397.

24.

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Sep 25;19(1):109. doi: 10.1186/s13058-017-0898-2. No abstract available.

25.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

26.

Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?

Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR.

Am J Surg. 2017 Dec;214(6):1082-1088. doi: 10.1016/j.amjsurg.2017.07.036. Epub 2017 Sep 18.

PMID:
28939252
27.

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Aug 7;19(1):91. doi: 10.1186/s13058-017-0884-8. Erratum in: Breast Cancer Res. 2017 Sep 25;19(1):109.

28.

Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer.

Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR.

Ann Surg Oncol. 2017 Oct;24(10):3073-3081. doi: 10.1245/s10434-017-5936-x. Epub 2017 Aug 1.

PMID:
28766195
29.

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L.

JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.

30.

Is complete response the answer?

Pusztai L, Szekely B, Hatzis C.

Ann Oncol. 2017 Aug 1;28(8):1681-1683. doi: 10.1093/annonc/mdx215. No abstract available.

PMID:
28633466
31.

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Jun 6;8:15759. doi: 10.1038/ncomms15759.

32.

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status.

Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT.

J Cancer. 2017 Apr 9;8(6):1045-1052. doi: 10.7150/jca.13690. eCollection 2017.

33.

Decreasing temperature enhances the formation of sixfold hydrogen bonded rings in water-rich water-methanol mixtures.

Bakó I, Pusztai L, Temleitner L.

Sci Rep. 2017 Apr 21;7(1):1073. doi: 10.1038/s41598-017-01095-7.

34.

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Apr 20;8:14944. doi: 10.1038/ncomms14944. Erratum in: Nat Commun. 2017 Jun 06;8:15759.

35.

Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.

Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, Pusztai L.

Cancer Res. 2017 Jun 15;77(12):3317-3324. doi: 10.1158/0008-5472.CAN-16-3478. Epub 2017 Apr 20.

36.

Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human cancer.

Chen C, Gu P, Wu J, Chen X, Niu S, Sun H, Wu L, Li N, Peng J, Shi S, Fan C, Huang M, Wong CC, Gong Q, Kumar-Sinha C, Zhang R, Pusztai L, Rai R, Chang S, Lei M.

Nat Commun. 2017 Apr 10;8:14929. doi: 10.1038/ncomms14929.

37.

Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.

Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS.

J Oncol Pract. 2017 May;13(5):e505-e515. doi: 10.1200/JOP.2016.018341. Epub 2017 Mar 7.

PMID:
28267392
38.

Is precision medicine ready for use in breast cancer?

Pusztai L.

Clin Adv Hematol Oncol. 2016 Dec;14(12):964-966. No abstract available.

PMID:
28212357
39.

New Therapeutic Strategies for Triple-Negative Breast Cancer.

Székely B, Silber AL, Pusztai L.

Oncology (Williston Park). 2017 Feb 15;31(2):130-7. Review.

40.

Reverse Monte Carlo modeling of liquid water with the explicit use of the SPC/E interatomic potential.

Pethes I, Pusztai L.

J Chem Phys. 2017 Feb 14;146(6):064506. doi: 10.1063/1.4975987.

PMID:
28201892
41.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2017 Jan 1;28(1):128-135. doi: 10.1093/annonc/mdw434.

42.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.

J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.

43.

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.

Bottai G, Diao L, Baggerly KA, Paladini L, Győrffy B, Raschioni C, Pusztai L, Calin GA, Santarpia L.

Int J Mol Sci. 2017 Jan 19;18(1). pii: E194. doi: 10.3390/ijms18010194.

44.

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.

Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C.

PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016 Dec.

45.

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C.

Cancer Res. 2017 Jan 15;77(2):566-578. doi: 10.1158/0008-5472.CAN-16-1901. Epub 2016 Nov 21.

46.

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C.

JAMA Oncol. 2016 Sep 29. doi: 10.1001/jamaoncol.2016.3824. [Epub ahead of print]

47.

Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.

Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C.

Biometrics. 2017 Jun;73(2):687-695. doi: 10.1111/biom.12590. Epub 2016 Sep 26.

48.

A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.

Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL, Thompson AM.

BMC Cancer. 2016 Sep 22;16(1):745.

49.

Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.

von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L.

Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6.

50.

Clinical Utility of Biomarker Tests in Decisions on Extended Endocrine Therapy.

Sanft T, Pusztai L.

J Clin Oncol. 2016 Nov 10;34(32):3942-3943. doi: 10.1200/JCO.2016.67.3285. No abstract available.

PMID:
27551119

Supplemental Content

Loading ...
Support Center